AUA 2018: A Novel Concept for Reporting Outcomes of a Successful Treatment in Endourology for Stones: The Stone-Fecta

San Francisco, CA USA (UroToday.com) Dr. Giovanni Cacciamani, a fellow from the University of Southern California, presented his data on a novel concept for a system for reporting outcomes during URS/RIRS for stones, titled the STONEfecta (Successful Treatment Outcomes in Endourology). Dr. Cacciamani and his team wanted to develop a system to track and influence management decisions of URS and RIRS procedures, as the number of treatments needed to reach stone free rates in the safest way possible in terms of infections and intraoperative complications represents a concern for both patients and surgeons.

AUA 2018: Emergency Room Utilization and Associated Costs for Pediatric vs. Adult Nephrolithiasis

San Francisco, CA USA (UroToday.com) Diana K. Bowen, MD, a Pediatric Urology Fellow from the Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, presented data that compared the frequency of visits and associated charges for emergency room encounters during a single stones episode between pediatric and adult patients.

AUA 2018: Percutaneous Cryoablation of Renal Tumors in Solitary Kidney: Results From an Italian Multicentric Study

San Francisco, CA USA (UroToday.com) Gaetano Chiapparrone from the Urologic Clinic of Azienda Sanitaria Universitaria Integrata di Trieste delivered a podium on their study assessing outcomes when using percutaneous cryoablation (PCA) in patients with a solitary kidney.

AUA 2018: Safety and Efficacy of Percutaneous US and CT Guided Microwave Ablation of T1a and T1b Renal tumors

San Francisco, CA USA (UroToday.com) Sepideh Shakeri of the Department of Radiology at the University of California Los Angeles delivered a podium on their study assessing the safety and efficacy of image-guided microwave ablation (MWA) in biopsy-proven renal cell carcinoma (RCC).

AUA 2018: Comparative Analysis of Perioperative Outcomes for Patients With 4-7cm RCC Treated with Either Microwave Ablation, Partial Nephrectomy or Radical Nephrectomy

San Francisco, CA USA (UroToday.com) Daniel D. Shapiro of the University of Wisconsin School of Medicine and Public Health delivered a podium on their study looking at perioperative outcomes in patients with 4 – 7 cm renal cell carcinoma (RCC) tumors treated with either microwave ablation (MWA) or nephrectomy.

AUA 2018: Exploration of Biomarkers Associated with Prognosis in Patients with Clear Cell Renal Cell Carcinoma Undergoing Surgical Resection by Desorption Electrospray Ionization Imaging Mass Spectrometry

San Francisco, CA USA (UroToday.com) Mr. Keita Tamura, clinical research urology associate from Hamamatsu University School of Medicine, presented data that evaluated the efficacy of a novel molecular anatomy technique, desorption electrospray ionization imaging mass spectrometry (DESI-IMS), to identify biomarkers from a range of lipids from and to predict the prognosis of patients with clear cell renal cell carcinoma (ccRCC). As an introduction, Mr. Tamura stated how although conventional mass spectrometry analysis is widely used to screen small biomolecules, it cannot distinguish between non-cancerous and cancerous tissues and produces false positives.

AUA 2018: Metabolomic Signatures in Urine from Renal Cell Carcinoma Patients

San Francisco, CA USA (UroToday.com) Annelise Bonvillain, MD, clinical research urology specialist from Emory University School of Medicine, presented data that evaluated if there were significant differences in the metabolomics of urine for patients with renal cell carcinoma (RCC). As an introduction, Ms. Bonvillain stated that RCC is the 7th most common cancer in men and 9th most common cancer in women in the US. The 5-year overall survival rate is less than 11.7%; however, early detection concurrent with conventional therapies exhibited 5-year survival rates of 92.5%.